Serum Institute to charge revised rates once Centre runs out of stock bought at Rs 150 a dose
Serum Institute of India's Covishield vaccine will cost private hospitals Rs 600 per dose and state governments Rs 400 per dose, a rate which will also apply to central government procurement, once the existing contract for Rs 150 a dose ends, its chief executive said on Wednesday. The world's largest vaccine maker announced the pricing of AstraZeneca shots it manufactures at its Pune facility, following the government decision to open up inoculation to all citizens above 18 years of age.
"Going ahead, 50 per cent of our capacities will be served to the Government of India's vaccination program, and the remaining 50 per cent of the capacity will be for the state governments and private hospitals," the Serum Institute of India (SII) said in a statement. With the government giving manufacturers and importers pricing freedom, SII said Covishield vaccines will be priced at Rs 400 per dose for state governments and Rs 600 for private hospitals.
The pricing, however, came in for sharp criticism from Opposition parties who saw no logic in charging state governments higher rates when the Centre was getting the same vaccine at Rs 150 per dose. SII CEO Adar Poonawalla later told CNBC-TV18 that the central government too will be charged Rs 400 once the initial contract for 100 million doses ends.
"Let me clarify, it is not a different price. All government prices will be Rs 400 henceforth for new contracts," he said.
"Please understand the Rs 150 price which is being thrown around has been for the central government for prior commitments and contracts. When that ceases to exist, after we supply about 100 million doses to them, which was ordered in bulk a long time ago, we will also charge Rs 400 to any government," he said. So, after opening up the policy, "the new price to the government is Rs 400 and for private hospitals, it is Rs 600," he said. "Also to put it in context, it is half or one-third the price of most global vaccines."
The previous pricing, Poonawalla said, was given without even knowing if the vaccine will work and it was a "risk-sharing price" that was agreed for a limited amount of quantities. "Now that the vaccine is licensed and is showing good efficacy, we have now announced, based on the new policy of the government, these prices," he said. He also said SII will be able to raise its monthly output of the AstraZeneca-Oxford University Covid-19 vaccine to 100 million doses by July from 60-70 million now, later than a previous timeline of end-May.
India initially immunised the most vulnerable but broadened that to anyone over 45 years on April 1 because of a surge in cases. It has now allowed all citizens over 18 years of age to get vaccinated from May 1.
In the statement, the company also said for the next two months, it will address the issue of limited capacity by scaling up vaccine production.
Considering the global vaccine prices, "we are ensuring that our vaccines are affordable in comparison to any other vaccines in the world", SII said.
The American vaccines in the private market cost more than Rs 1,500 per dose, while Russian and Chinese jabs cost more than Rs 750 per dose, it added.
"... owing to the complexity, and urgency of the situation it is challenging to supply it independently to each corporate entity. We would urge all corporate and private individuals to access the vaccines through the state facilitated machinery and private health systems," SII said. After four to five months, the vaccines will be made available in retail and free trade, it added. The vaccine major said it welcomes the recent announcement made by the Ministry of Health and Finance Ministry to accelerate India's vaccination drive.
"The promising directives will help to scale up vaccine production, and allow state governments, private hospitals, and vaccination centers to procure vaccines directly," it added. On Tuesday, Poonawalla had tweeted, "On behalf of the vaccine industry in India, I would like to thank and applaud Narendra Modi, Nirmala Sitharaman for your decisive policy changes and swift financial aid which will help vaccine production and distribution in India."
Covishield comprises over 90 per cent of the 12.76 crore Covid-19 vaccines administered across the country so far, according to government data on Wednesday. Of the 127,605,870 Covid-19 vaccination jabs administered till now, 11,60,65,107 are of Covishield, while 1,15,40,763 are Covaxin, according to the government's Co-Win portal.
According to sources, the government is likely to waive 10 per cent customs duty levied on imported vaccines in a bid to keep the cost of overseas jabs low. The overseas vaccines are being eyed to supplement domestically made shots ahead of the opening of Covid-19 vaccination to all citizens over 18 years of age.